Aligos Therapeutics SEC filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing therapies for liver and viral diseases. Its Form 8-K reports furnish results of operations, business progress updates, clinical and regulatory events for pevifoscorvir sodium, and material agreements such as the exclusive license for development and commercialization in Greater China.
Proxy materials cover annual meeting procedures, stockholder voting matters, board governance, and compensation-related disclosures. Other current reports document executive officer appointments, compensatory arrangements, exhibit filings, and the company’s common stock listed on the Nasdaq Capital Market under ALGS.
Aligos Therapeutics (NASDAQ: ALGS) filed a routine Form 4 disclosing an insider stock-option grant to director Margarita Chavez.
On June 25 2025, Chavez received an option to purchase 5,860 common shares at an exercise price of $7.63. The option vests 100 % on the earlier of the first anniversary of the grant or immediately prior to the company’s 2026 annual meeting, and expires on June 25 2035. No shares were bought or sold in the open market, and beneficial ownership remains unchanged except for the new option award.
The filing appears to reflect standard board compensation and does not indicate any material change in corporate strategy, financial condition, or insider sentiment.
Aligos Therapeutics (NASDAQ:ALGS) filed a routine Form 4 disclosing an insider grant. On June 25 2025, director Bridget A. Martell was awarded 5,860 stock options with a strike price of $7.63 per share. The options vest 100 % on the earlier of the first anniversary of the grant date or immediately before the 2026 annual shareholder meeting and expire on June 25 2035. After the transaction, Martell beneficially owns 5,860 derivative securities. No open-market purchases or sales of ALGS common stock were reported.
Aligos Therapeutics (Nasdaq:ALGS) filed an 8-K disclosing results of its June 25, 2025 Annual Meeting.
- Authorized share increase: voting common stock rises from 20 million to 100 million; non-voting common stock from 0.8 million to 15.8 million (Item 5.03).
- Equity plan expansion: 2020 Incentive Award Plan enlarged by 1,000,000 shares (Item 5.02).
- All proposals passed with c.~87% support; three Class II directors re-elected and Ernst & Young ratified as auditor (Item 5.07).
- Shares outstanding on record date: 5,314,801.
The amendments give management broad capacity to issue new equity for financing or compensation, but materially raise dilution risk for existing holders. No financial results were reported.